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Since Burch et al.1) first introduced the terminology “ischemic 
cardiomyopathy (ICM),” it has been widely used in clinical practice. The 
condition may originate from prolonged ischemia, a single large infarct, 
or repeated micro-infarcts inducing left ventricular dysfunction and 
remodeling through apoptosis and fibrosis as a result of activation 
of the endothelin or renin-angiotensin-aldosterone system.2) It can 
be reversed after successful revascularization in the presence of 
a viable myocardium. However, there have been several debates 
about the actual existence of that kind of cardiomyopathy. Because 
traditionally cardiomyopathy is a result of a genetically or acquired 
disease-driven myopathic processes, current WHO criteria do not 
include ICM in the classification of cardiomyopathy.3) But in many 
clinical practices and studies, an initial classification as ICM or 
non-ICM is widely used in patients with severely depressed left 
ventricular function. Use of the terminology “ICM or non-ICM” 
persists in spite of a lack of official guidelines because it can 
provide a simple and easily communicated understanding of the 
underlying pathogenesis and treatment options. A myocardium 
that is malfunctioning from prolonged ischemia can be improved 
after successful revascularization treatment, such as coronary 
artery bypass surgery. If a patient is classified as non-ICM, then 
a search for other causes must be begun. However, the current 
definition of ICM is vague and cannot fully explain the cause of 
severely depressed left ventricular dysfunction.4) In addition, as 
a previous study showed, ICM with post-myocardial infarction 
has a far different prognosis from ICM without post-myocardial 
infarction5); the underlying causes of non-post myocardial 
infarction ICM are very complex and cannot be easily explained 
by the concept of a hibernating myocardium. This complexity 
may explain the unexpected dearth of positive outcomes in the 
“Surgical Treatment for Ischemic Heart Failure” trial, such as 
improved survival, according to viability tests, following bypass 
surgery in patients with ICM.6)  
In this regard, a study done by Kim et al.7) provides important 
insight about possible misclassification as ICM or non-ICM based on 
the traditional definition using coronary angiography and a history 
of previous myocardial infarction. According to their observations 
with delayed hyper-enhancement (DHE)-cardiac magnetic resonance 
(CMR), some cases classified as ICM had non-ischemic DHE patterns, 
such as midwall striae, patch, or subepicardial DHE. Also, a small 
portion of non-ICM patients had ischemic DHE patterns, such 
as subendocardial DHE. They suggested that the classification of 
ICM should be individualized after considering DHE-CMR findings. 
According to their observations, some patients with ICM showed 
midwall linear DHE, which is a unique finding related to prognosis 
in non-ICM cases.8) It provides new insight into the pathology 
of left ventricular dysfunction in these patients and also the 
pathophysiology of midwall DHE, which is believed to be from 
prior myocarditis or an increase in gadolinium diffusion distance 
due to high wall stress.9) However, no satisfactory explanation has 
been proposed because usually the amount of interstitial fibrosis 
is highest in the subepicardium, not the midwall, in non-ICM 
patients.10) 
The study done by Kim et al.7) has a limitation in that identification 
of ICM without prior myocardial infarction requires evaluation for 
the presence of myocardial perfusion defects because DHE only 
represents replacement fibrosis. Therefore, patients without DHE 
and with non-DHE regions also need to be characterized to explain 
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severely depressed left ventricular systolic function. To overcome 
this limitation, inclusion of new parameters such as myocardial 
flow reserve or extracellular space volume fraction would be 
helpful. In addition, a large-scale study can provide clarity on the 
clinical characteristics of this discordant population.   
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